Drug delivery and systemic glaucoma effects

Principles of Ophthalmic Drug Delivery & Pharmacokinetics

Topical ocular drug administration is governed by rigorous anatomical, biochemical, and physiological barriers. For a topically instilled therapeutic to achieve therapeutic concentrations within the anterior chamber, it must navigate the unique trilaminar structure of the cornea:

The Corneal Trilayer Diffusion Barrier

1. Corneal Epithelium (Lipophilic Barrier): Composed of 5 to 6 cellular layers with continuous superficial tight junctions (zonula occludens). It provides high electrical resistance ($>1000\ \Omega\cdot\text{cm}^2$) and blocks the paracellular transit of hydrophilic molecules. Only lipid-soluble (non-ionized) molecules can diffuse transcellularly across the epithelium.
2. Corneal Stroma (Hydrophilic Barrier): Comprises $90\%$ of total corneal thickness, consisting of hydrated, highly ordered type I and V collagen fibrils embedded in a ground substance rich in glycosaminoglycans (keratan sulfate and chondroitin sulfate). It acts as an impenetrable barrier to highly lipophilic compounds, permitting only water-soluble (ionized) substances to pass.
3. Corneal Endothelium (Lipophilic Monolayer): A single monolayer of hexagonal cells joined by discontinuous macula adherens. While lipid-rich, its junctions permit passive paracellular transit of small hydrophilic macromolecules between the stroma and the anterior chamber aqueous humor.

The Biphasic Solubility Requirement & Henderson-Hasselbalch Kinetics

Because a drug must traverse both the lipophilic epithelium and the hydrophilic stroma to enter the anterior chamber, topically active ocular pharmaceuticals must possess biphasic solubility (both lipid and water solubility). Most ophthalmic drugs are weak bases (e.g., timolol, tropicamide) or weak acids. In aqueous solution, they exist in dynamic equilibrium between non-ionized (uncharged, lipophilic) and ionized (charged, hydrophilic) states, governed by the Henderson-Hasselbalch equation:

For a weak base, $\text{pH} = \text{p}K_a + \log([B]/[BH^+])$. For a weak acid, $\text{pH} = \text{p}K_a + \log([A^-]/[HA])$. The ionised-to-unionised ratio therefore responds in opposite directions for the two classes.

The uncharged fraction often crosses the corneal epithelium more readily, while stromal passage also depends on aqueous solubility. Ionisation, concentration, formulation, tear clearance and epithelial integrity together determine delivery; a drug is not compelled to switch completely between charged and uncharged states at each layer.

Systemic Absorption & The Role of Punctal Occlusion

• Drop Volume Discrepancy: A standard commercial eyedrop bottle dispenses a droplet volume of $30$ to $50\ \mu\text{L}$. However, the normal precorneal tear film volume is only $7$ to $10\ \mu\text{L}$, with a maximal holding capacity of the conjunctival sac of approximately $25-30\ \mu\text{L}$ without blinking. Consequently, $>80\%$ of an instilled drop immediately overflows onto the cheek or drains rapidly through the upper and lower puncta into the nasolacrimal drainage system.
• Systemic exposure: Nasal mucosal absorption can bypass hepatic first-pass metabolism and cause clinically significant adverse effects. Absorption is variable and topical dosing is not equivalent to an intravenous injection. Gentle lid closure and nasolacrimal occlusion reduce exposure.
• Digital Punctal Occlusion Technique: Applying direct digital pressure over the medial canthus (puncta and common canaliculus) accompanied by gentle eyelid closure for $2$ to $3$ minutes following drop instillation prevents drainage into the nasolacrimal duct. This simple clinical intervention decreases systemic drug absorption by $60-70\%$ and increases intraocular bioavailability by up to $40\%$.

Systemic Toxicities & Contraindications of Topical Glaucoma Medications

Topical anti-glaucoma agents exert potent systemic pharmacological actions. EBOD candidates must demonstrate comprehensive command of their systemic toxicities and absolute contraindications: